Publications by authors named "N L Sicotte"
Incorporation of the central vein sign into the McDonald criteria.
Mult Scler Relat Disord
November 2024
Background: Diagnosis of multiple sclerosis (MS) frequently relies on MRI dissemination in time (DIT) and space (DIS), as codified in 2017 McDonald criteria (McD 2017). The central vein sign (CVS) is a proposed MS diagnostic biomarker, but its optimal incorporation into McD 2017 has not been extensively studied.
Objective: Evaluate the diagnostic performance of several methods incorporating CVS into McD 2017 radiological DIS criteria.
Background And Purpose: Paramagnetic rim lesions (PRLs) are an MRI biomarker of chronic inflammation in people with multiple sclerosis (MS). PRLs may aid in the diagnosis and prognosis of MS. However, manual identification of PRLs is time-consuming and prone to poor interrater reliability.
View Article and Find Full Text PDFArticle Synopsis
- The central vein sign (CVS) is a proposed biomarker for diagnosing multiple sclerosis (MS) but traditional manual ratings for assessing CVS lesions can be slow and inconsistent.
- This study compared an automated CVS detection method to manual rating in 86 participants being evaluated for MS using 3T MRI scans.
- Results showed the automated method had a similar effectiveness in distinguishing MS patients from non-patients as the manual methods, with an area under the curve (AUC) ranging between 0.78 and 0.89, depending on the method used.
Article Synopsis
- The study evaluates the effectiveness of simplified imaging methods (central vein sign or CVS) compared to cerebrospinal fluid oligoclonal bands (OCB) as diagnostic tools for multiple sclerosis (MS).
- Results indicate that both methods have similar sensitivity and specificity, with a higher positive predictive value (PPV) for the CVS method after 12 months.
- Further research is planned to determine if CVS can replace or work alongside OCB for diagnosing MS.
Article Synopsis
- About 6.9 million Americans have Alzheimer’s dementia, with Lecanemab showing some promise in slowing decline for those with mild symptoms, but it comes with risks of brain-related side effects.
- Lecanemab requires patients to have biweekly infusions and continuous monitoring, which adds complexity to treatment and demands a team approach for safety and effectiveness.
- The way Lecanemab treatment is organized can help guide future management strategies for new therapies in neurology and potentially other medical fields.